
NPA’s Fabricant on NMN: ‘Taking FDA to Federal Court is expensive, but I don’t see another option’
The US Food and Drug Administration (FDA) has been unable to reach a decision on the requests made in a Citizen Petition about NMN due to “competing agency priorities”, a response that threatens the NMN sector, says Daniel Fabricant, PhD.


